Stable, tested and effective staphylococcal vaccine

Immunology Laboratories, Inc.

The Road Ahead… Ultimate Accomplishment of the Mission

Due to the very substantial capital requirements, compared to the very limited financial resources available to ImmLab at this point, accomplishment of the mission, although quite probable, is projected to be a very lengthy process. And during this lengthy time period, the ultimate beneficiaries of the technology (humans and animals suffering from staphylococcal infections) will remain untreated. We expect the cost of waiting, in financial as well as physical terms, for the ultimate beneficiaries to be very substantial. Therefore, ImmLab’s stockholders and advisors have determined that it is in the best interest of all involved to aggressively pursue alternatives for expediting the process of bringing the products to the availability of practicing physicians, veterinarians and scientists throughout the world.

ImmLab’s business can be summarized into three, very basic, divisions: 

         1. Human applications

         2. Large animal applications

         3. Companion and fur-bearing animal applications 

ImmLab’s stockholders and advisors are very interested in the possibility of creating a strategic alliance with a mature pharmaceutical firm with the financial resources, as well as human capital, sufficient to bring the products to the marketplace for any (or all) of the three divisions. This alliance should enable ImmLab to continue scientific research projects to determine various uses for the current products, make improvements to the current products and develop new (but related) products. ImmLab’s scientists are confident that the pipeline will continue for many years to come as a result of the technology that is now in ImmLab’s possession.

At this point, it seems appropriate to create some form of a partnering agreement with the reputable firm that is most appropriate for, and capable of, implementing the most efficient plan to accomplish the ultimate mission. ImmLab's stockholders and advisors feel that a merger or an acquisition would be the most appropriate forms of alliance with another firm. However, we are also open to discussion of other plans that would possibly achieve the desired outcome.

At the foundation of ImmLab’s accomplishments is the highest level of ethics and integrity. We are unwilling to compromise that level of ethics and integrity. We will only consider transactions that will benefit all involved. 

Our mission

Our mission is to significantly improve the prevention and treatment of microbial infections. In particular, we are focused on increasing the treatment options for people infected with the Staphylococcus aureus(S. aureus). The technology we have developed has particular application for the treatment and prevention of infections by antibiotic resistant strains of S. aureus. A key target population for our technology is the group of individuals at increased risk of exposure to and infection by S. aureus strains, especially antibiotic resistant strains such as methicillin-resistant strains (MRSA), vancomycin-intermediate strains (VISA) and vancomycin-resistant strains (VRSA). ImmLab technology would have a role for pre-treatment of those facing elective surgery or any other non-urgent invasive treatment.  

In addition to use in human populations, ImmLab’s products have important application in the dairy industry by providing a non-antibiotic option for preventing staphylococcal infection of the udder (mastitis) in calves, before the calves reach a productive age. Additional non-human uses include the use of ImmLab’s products for treatment of S. aureus skin infections in small animals, including companions and fur bearing animals. 

We are dedicated to using our technology platform to extend the applications and products to treatment and prevention of infections such as a new emerging staphylococcal strain ST398 and other bacterial strains according to actual epidemiological situation.  The technology and product line being developed by ImmLab will not only improve the health and well-being of people and animals subject to microbial infection, but will do so using an approach that will not add to the growing threat of antibiotic resistant bacterial strains. 

Immlab’s technologies make it possible to manufacture novel preparations that contain biologically active components derived from S. aureus. The biologically active components in ImmLab's therapeutic preparations activate both innate and acquired immunity, including humoral and cell-mediated responses. Treatments with ImmLab’s preparations are efficient, cost-effective and may easily be carried out with nasal drops or injections for human use, as well as injections for animal use. Therefore, ImmLab’s commitment is to improve the diagnostics, treatment and prevention of bacterial infections.  ImmLab will provide innovative, practical and top-quality products that will improve the health of humans and animals suffering from life threatening infections due to existing and emerging antibiotic-resistant bacterial strains.

ImmLab is interested in creating a partnering, merge or acquisition relationship.


ImmLab was founded in 1997 and incorporated in Alabama, USA in 1998. ImmLab performs continuous research in Immunology, Microbiology and Proteomics of its present and future products at ImmLab's subsidiary in EU.